Results 141 to 150 of about 4,909,303 (275)

Air Pollution Quinones Impair Intestinal Barrier Integrity and Endoplasmic Reticulum in Differentiated Caco‐2 Cells

Journal of Applied Toxicology, EarlyView.
ABSTRACT Particulate matter (PM) is a major global health threat, linked to millions of deaths annually. Beyond inhalation, PM components reach the gastrointestinal tract through the mucociliary escalator or contaminated food and water. Among PM's organic fraction, redox‐active quinones such as 1,2‐naphthoquinone (NQ) and 9,10‐phenanthrenequinone (PQ ...
Franco Cervellati, Giulia Trinchera, Alice Casoni, Alessandra Pecorelli, Mascia Benedusi, Maria Chiara Pietrogrande, Giuseppe Valacchi   +6 more
wiley   +1 more source

Organ‐Specific Human Microbiomes and Dysbiosis: Mechanistic Links to Disease and Emerging Therapeutic Strategies

Journal of Clinical Laboratory Analysis, EarlyView.
Schematic overview of the human microbiome and major microbiota‐derived metabolites across body sites, highlighting the gut–brain, gut–heart, and gut–kidney axes in host physiology and disease. ABSTRACT Background The human microbiome is a dynamic and diverse community of microorganisms that affects susceptibility to illness and promotes wellness ...
Awadh Alanazi
wiley   +1 more source

Complicated Acute Appendicitis Conservatively Treated in Two Patients With Crohn's Disease: The Role of Intestinal Ultrasound and Contrast‐Enhanced Ultrasound

Journal of Clinical Ultrasound, EarlyView.
Intestinal ultrasound and contrast‐enhanced ultrasound were used to diagnose, monitor, and guide conservative treatment of complicated acute appendicitis in two patients with Crohn's disease. Serial imaging enabled early identification of treatment response, allowing long‐term surgery‐free outcomes.
Cataletti Giovanni, Gridavilla Daniele, Nylund Kim, Colombo Francesco, Danelli Piergiorgio, Maconi Giovanni   +5 more
wiley   +1 more source

Health Technology Assessment of Infliximab: A Rapid Review of Type 2 Studies

مجله دانشکده پزشکی اصفهان, 2012
Background: Infliximab has been used for treatment of patients with Crohn's disease whose symptoms or developed fistula could not be eliminated by standard treatments.
Mohamadreza Mobinizadeh, Alireza Oliyaeemanesh, Sheila Doaee, Mina Nejati, Parisa Aboee, Mahdi Azadbakht, Mahboubeh Valadkhani6   +6 more
doaj  

National trends in pathogen‐specific diagnoses and outcomes among hospitalizations for infectious diarrhea

Journal of Hospital Medicine, EarlyView.
Abstract Background The diagnostic evaluation of infectious diarrhea has evolved with increasing adoption of multiplex gastrointestinal nucleic acid amplification tests and changing diagnostic strategies for Clostridioides difficile. Objectives We aimed to assess changes in inpatient pathogen‐specific documentation rates and clinical outcomes on a ...
David Wong Arias, Spencer R. Goble, Mauricio Torrealba   +2 more
wiley   +1 more source

Nutritional and environmental determinants of maturation and disruption of the early life gut microbiome: A narrative review

Journal of Parenteral and Enteral Nutrition, EarlyView.
Abstract The first 1000 days of life represent a critical window for gut microbiome assembly, with lifelong implications for child growth, immune development, and disease risk. This review synthesizes evidence on maternal, perinatal, and especially nutritional factors that influence early‐life intestinal colonization and highlights the consequences of ...
Carly Burow, Romy Shenderey, Fariha Chowdhury, Nyah Shah, Nikhil Pai   +4 more
wiley   +1 more source

Gut microbiome in pediatric acute pancreatitis and Crohn's disease versus irritable bowel syndrome and healthy controls

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Pediatric acute pancreatitis (AP), Crohn's disease (CD), and irritable bowel syndrome (IBS) are associated with gut dysbiosis, but differences and similarities between conditions are unknown. We hypothesized that gut microbial ecology would differ across these disorders. Methods Stool was collected from 120 subjects (AP [n = 30], CD
Neha R. Santucci, Chinenye R. Dike, Jenny Hellmann, Nicholas J. Ollberding, Qing Duan, Philip Minar, Lee A. Denson, David B. Haslam, Daniel Castillo, Maisam Abu‐El‐Haija   +9 more
wiley   +1 more source

Exclusive enteral nutrition containing transforming growth factor‐β improves intestinal barrier function in a colitis mouse model

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Exclusive enteral nutrition (EEN) is the first‐line treatment for pediatric Crohn's disease, but its mechanisms of action remain poorly understood. Our aim was to identify the mechanisms that could explain the anti‐inflammatory effects of EEN, studying the nutritional composition and transforming growth factor‐β (TGF‐β) effects, in ...
Kawthar Boumessid, Vickie Lacroix, Ekaterina Ovtchinnikova, Sophie Thenet, Marie Carriere, Frédérick Barreau, Emmanuel Mas   +6 more
wiley   +1 more source

Early‐life adverse events and risk of inflammatory bowel disease: A Scandinavian birth cohort study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives The experience of childhood stressful or adverse life events is believed to imprint on immunological pathways and, therefore, might have lasting effects on inflammatory bowel disease (IBD) development. This study aimed to examine the association between experiences of early‐life adverse events and later IBD risk. Methods We followed
Ida Sigvardsson, Ketil Størdal, Henrik Imberg, Elisabeth Fernell, Christopher Gillberg, Johnny Ludvigsson, Karl Mårild   +6 more
wiley   +1 more source

Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti‐tumor necrosis factor alpha therapy in children

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell, Carlie Bolles, Claire R. Reilly, Manal Morgan, Christopher Burgess, Fariha Balouch, Peter J. Lewindon   +6 more
wiley   +1 more source